



PTO/SB/08B (08-03)

Approved for use through 07/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known	
		Application Number	10/813,177
		Filing Date	03/29/04
		First Named Inventor	Wei Gu
		Art Unit	1646
		Examiner Name	to be assigned
Sheet 1	of 16	Attorney Docket Number	5199-178

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/B.F./		Appella and Anderson, Signaling to p53: breaking the posttranslational modification code.	
/B.F./		Pathol. Biol. (Paris), 48:227-45, 2000	
/B.F./		Ashcroft et al., Regulation of p53 function and stability by phosphorylation.	
		Mol. Cell Biol., 19:1751-58, 1999	
		Ashcroft et al., Stress signals utilize multiple pathways to stabilize p53.	
		Mol. Cell Biol., 20:3224-33, 2000	
		Ashcroft and Vousden, Regulation of p53 stability.	
		Oncogene, 18:7637-43, 1999	
		Barak et al., mdm2 expression is induced by wild type p53 activity.	
/B.F./		EMBO J., 12:461-68, 1993	

Examiner Signature	/Brandon Fetterolf/	Date Considered	10/12/2007
-----------------------	---------------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known	
		Application Number	10/813,177
		Filing Date	03/29/04
		First Named Inventor	Wei Gu
		Art Unit	1646
		Examiner Name	to be assigned
Sheet 2	of 16	Attorney Docket Number	5199-178

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/B.F./		Beers and Berkow (eds.), The Merck Manual of Diagnosis and Therapy, 17th ed. (Whitehouse Station, NJ: Merck Research Laboratories, 1999)	
		973-74, 976, 986, 988, 991 (N/A)	
		Blattner et al., DNA damage induced p53 stabilization: no indication for an involvement of p53 phosphorylation.	
		Oncogene, 18:1723-32, 1999	
		Bodansky, M., Principles of Peptide Synthesis (New York: Springer-Verlag New York, Inc., 1984	
		Botchkarev et al., p53 is essential for chemotherapy-induced hair loss.	
↓		Cancer Res., 60:5002-02, 2000	
/B.F./		Brooks and Gu, Ubiquitination, phosphorylation and acetylation: the molecular basis for p53 regulation.	
		Curr. Opin. Cell Biol., 15:164-71, 2003 (N/A)	

Examiner Signature	/Brandon Fetterolf/	Date Considered	10/12/2007
--------------------	---------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.9C. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known	
		Application Number	10/813,177
		Filing Date	03/29/04
		First Named Inventor	Wei Gu
		Art Unit	1646
		Examiner Name	to be assigned
Sheet 3 of 16	Attorney Docket Number	5199-178	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/B.F./		Chen et al. (Mapping of the p53 and mdm-2 interaction domains.	
		Mol. Cell. Biol., 13:4107-14, 1993	
		Chung and Baek, Deubiquitinating enzymes: their diversity and emerging roles.	
		Biochem. Biophys. Res. Commun., 266: 633-640, 1999	
		D'Andrea and Pellman, Deubiquitinating enzymes: a new class of biological regulators.	
		Crit. Rev. Biochem. Mol. Biol., 33:337-52, 1998	
		de Graaf et al., Hdmx protein stability is regulated by the ubiquitin ligase activity of Mdm2.	
		J. Biol. Chem., 278:38315-324, 2003	
		Donehower et al., Mice Deficient for p53 are developmentally normal but susceptible to spontaneous tumours.	
/B.F./		Nature, 356:215-21, 1992	

Examiner Signature	/Brandon Fetterolf/	Date Considered	10/12/2007
--------------------	---------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known	
		Application Number	10/813,177
		Filing Date	03/29/04
		First Named Inventor	Wei Gu
		Art Unit	1646
		Examiner Name	to be assigned
Sheet 4	of 16	Attorney Docket Number	5199-178

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/B.F./		Dumaz and Meek, Serine15 phosphorylation stimulates p53 transactivation but does not directly influence interaction with HDM2.	
		EMBO J., 18:7002-10, 1999	
		el-Deiry et al., WAF1, a potential mediator of p53 tumor suppression.	
		Cell, 75:817-825, 1993	
		Everett et al., A novel ubiquitin-specific protease is dynamically associated with the PML nuclear domain and binds to a herpesvirus regulatory protein.	
		EMBO J., 16:566-77, 1997	
		Finch et al., Mdmx is a negative regulator of p53 activity in vivo.	
		Cancer Res., 62:3221-225, 2002	
↓		Freedman et al., Functions of the MDM2 oncoprotein.	
/B.F./		Cell Mol. Life Sci., 55:96-107, 1999	

Examiner Signature	/Brandon Fetterolf/	Date Considered	10/12/2007
--------------------	---------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known	
		Application Number	10/813,177
		Filing Date	03/29/04
		First Named Inventor	Wei Gu
		Art Unit	1646
		Examiner Name	to be assigned
Sheet 5	of 16	Attorney Docket Number 5199-178	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/B.F./		Giaccia and Kastan, The complexity of p53 modulation: emerging patterns from divergent signals.	
		Genes Dev., 12:2973-83, 1998	
		Gu et al., Mutual dependence of MDM2 and MDMX in their functional inactivation of p53.	
		J. Biol. Chem., 277:19251-254, 2002	
		Gu et al., Synergistic activation of transcription by CBP and p53.	
		Nature, 387:819-23, 1997	
		Haupt et al., Mdm2 promotes the rapid degradation of p53.	
		Nature, 387:296-99, 1997	
↓		Hemann et al., An epi-allelic series of p53 hypomorphs created by stable RNAi produces distinct tumor phenotypes in vivo.	
/B.F./		Nat. Genet., 33:396-400, 2003 (N/A)	

Examiner Signature	/Brandon Fetterolf/	Date Considered	10/12/2007
--------------------	---------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known	
		Application Number	10/813,177
		Filing Date	03/29/04
		First Named Inventor	Wei Gu
		Art Unit	1646
		Examiner Name	to be assigned
Sheet 6	of 16	Attorney Docket Number 5199-178	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/B.F./		Hengstermann et al., Complete switch from Mdm2 to human papillomavirus E6-mediated degradation of p53 in cervical cancer cells.	
		Proc. Natl. Acad. Sci. USA, 98:1218-23, 2001	
		Hershko et al., The ubiquitin system.	
		Nat. Med., 6:1073-81, 2000	
		Hicke and Dunn, Regulation of membrane protein transport by ubiquitin and ubiquitin-binding proteins.	
		Annu. Rev. Cell Dev. Biol., 19:141-72, 2003	
		Hollstein et al., Database of p53 gene somatic mutations in human tumors and cell lines.	
		Nucleic Acids Res., 22:3551-55, 1994	
↓		Hollstein et al., New approaches to understanding p53 gene tumor mutation spectra.	
/B.F./		Mutat. Res., 431:199-209, 1999	

Examiner Signature	/Brandon Fetterolf/	Date Considered	10/12/2007
--------------------	---------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known	
		Application Number	10/813,177
		Filing Date	03/29/04
		First Named Inventor	Wei Gu
		Art Unit	1646
		Examiner Name	to be assigned
Sheet 7	of 16	Attorney Docket Number 5199-178	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/B.F./		Holowaty et al., Protein interaction domains of the ubiquitin-specific protease, USP7/HAUSP.	
		J. Biol. Chem., 278: 47753-47761, 2003	
		Holowaty et al., Protein profiling with Epstein-Barr nuclear antigen-1 reveals an interaction with the herpesvirus-associated ubiquitin-specific protease HAUSP/USP7.	
		J. Biol. Chem., 278:29987-994, 2003	
		Honda et al., Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53.	
		FEBS Lett., 420:25-27, 1997	
		Jones et al., Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53.	
/B.F./		Nature, 378:206-08, 1995	

Examiner Signature	/Brandon Fetterolf/	Date Considered	10/12/2007
--------------------	---------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/813,177
Filing Date	03/29/04
First Named Inventor	Wei Gu
Art Unit	1646
Examiner Name	to be assigned
Attorney Docket Number	5199-178

Sheet 8

of

16

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/B.F./		Kamijo et al., Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF.	
		Cell, 91:649-59, 1997	
		Kastan et al., A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia.	
		Cell, 71:587-97, 1992	
		Kawai et al., DNA damage-induced MDMX degradation is mediated by MDM2.	
		J. Biol. Chem., 278:45946-953, 2003	
		Kornitzer and Ciechanover, Modes of regulation of ubiquitin-mediated protein degradation.	
		J. Cell. Phys., 182:1-11, 2000	
		Kubbutat et al., Regulation of p53 stability by Mdm2.	
/B.F./		Nature, 387:299-303, 1997	

Examiner
Signature

/Brandon Fetterolf/

Date
Considered

10/12/2007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known	
		Application Number	10/813,177
		Filing Date	03/29/04
		First Named Inventor	Wei Gu
		Art Unit	1646
		Examiner Name	to be assigned
Sheet 9	of 16	Attorney Docket Number 5199-178	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/B.F./		Lane, D.P., p53, guardian of the genome.	
		Nature, 358:15-16, 1992	
		Laney and Hochstrasser, Substrate targeting in the ubiquitin system.	
		Cell, 97:427-30, 1999	
		Levine, A.J., p53, the cellular gatekeeper for growth and division.	
		Cell, 88:323-31, 1997	
		Linares et al., HdmX stimulates Hdm2-mediated ubiquitination and degradation of p53.	
		Proc. Natl. Acad. Sci. USA, 100:12009-014, 2003	
		Luo et al., Deacetylation of p53 modulates its effect on cell growth and apoptosis.	
/B.F./		Nature, 408:377-81, 2000	

Examiner Signature	/Brandon Fetterolf/	Date Considered	10/12/2007
-----------------------	---------------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/813,177
Filing Date	03/29/04
First Named Inventor	Wei Gu
Art Unit	1646
Examiner Name	to be assigned
Attorney Docket Number	5199-178

Sheet 10

of

16

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/B.F./		Luo et al., Negative control of p53 by Sir2• promotes cell survival under stress.	
		Cell, 107:137-48, 2001	
		Lowe and Sherr, Tumor suppression by Ink4a-Arf: progress and puzzles.	
		Curr. Opin. Genet. Dev., 13:77-83, 2003 (N/A)	
		Michael and Oren, The p53-Mdm2 module and the ubiquitin system.	
		Semin. Cancer Biol., 13:49-58, 2003	
		Migliorini et al., Mdm4 (Mdmx) regulates p53-induced growth arrest and neuronal cell death during early embryonic mouse development.	
		Mol. Cell Biol., 22:5527-38, 2002	
/B.F./		Modern Techniques of Peptide and Amino Acid Analysis (New York: John Wiley & Sons, 1981 (N/A))	

Examiner
Signature

/Brandon Fetterolf/

Date
Considered

10/12/2007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/813,177
Filing Date	03/29/04
First Named Inventor	Wei Gu
Art Unit	1646
Examiner Name	to be assigned
Attorney Docket Number	5199-178

Sheet 11

of

16

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/B.F./		Montes de Oca Luna et al., Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53.	
		Nature, 378:203-06, 1995	
		Munger and Howley, Human papillomavirus immortalization and transformation functions.	
		Virus Res., 89:213-28, 2002	
		Nakano and Vousden, PUMA, a novel proapoptotic gene, is induced by p53.	
		Molecular Cell, 7:683-94, 2001	
		Oda et al., Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis.	
		Science, 288:1053-58, 2000a	
↓		Oda et al., p53AIP1, a potential mediator of p53-dependent apoptosis, and its regulation by Ser-46-phosphorylated p53.	
/B.F./		Cell, 102:849-62, 2000b	

Examiner
Signature

/Brandon Fetterolf/

Date
Considered

10/12/2007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known	
		Application Number	10/813,177
		Filing Date	03/29/04
		First Named Inventor	Wei Gu
		Art Unit	1646
		Examiner Name	to be assigned
Sheet 12 of 16	Attorney Docket Number	5199-178	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/B.F./		Okamoto and Beach, Cyclin G is a transcriptional target of the p53 tumor suppressor protein.	
		EMBO J., 13:4816-22, 1994	
		Oren, M., Regulation of the p53 tumor suppressor protein.	
		J. Biol. Chem., 274, 36031-034, 1999	
		Pan and Chen, MDM2 promotes ubiquitination and degradation of MDMX.	
		Mol. Cell Biol., 23:5113-21, 2003	
		Parant et al., Rescue of embryonic lethality in Mdm4-null mice by loss of Trp53 suggests a non-overlapping pathway with MDM2 to regulate p53.	
		Nat. Genet., 29:92-95, 2001	
		Pickart, C.M., Back to the future with ubiquitin.	
↓			
/B.F./		Cell, 116:181-90, 2004	

Examiner Signature	/Brandon Fetterolf/	Date Considered	10/12/2007
--------------------	---------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known	
		Application Number	10/813,177
		Filing Date	03/29/04
		First Named Inventor	Wei Gu
		Art Unit	1646
		Examiner Name	to be assigned
Sheet 13 of 16	Attorney Docket Number	5199-178	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/B.F./		Prives and Hall, The p53 pathway.	
		J. Pathol., 187:112-26, 1999	
		Rodriguez et al., Multiple C-terminal lysine residues target p53 for ubiquitin-proteasome-mediated degradation.	
		Mol. Cell. Biol., 20:8458-67, 2000	
		Scheffner et al., The HPV-16 E6 and E6-AP complex functions as an ubiquitin-protein ligase in the ubiquitination of p53.	
		Cell, 75:495-505, 1993	
		Seavey et al., The E7 oncoprotein of human papillomavirus type 16 stabilizes p53 through a mechanism independent of p19 (ARF).	
		J. Virol., 73:7590-98, 1999	
		Sherr, C.J., The INK4a/ARF network in tumour suppression.	
/B.F./		Nat. Rev. Mol. Cell Biol., 2:731-37, 2001	

Examiner Signature	/Brandon Fetterolf/	Date Considered	10/12/2007
--------------------	---------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known	
		Application Number	10/813,177
		Filing Date	03/29/04
		First Named Inventor	Wei Gu
		Art Unit	1646
		Examiner Name	to be assigned
Sheet 14	of 16	Attorney Docket Number 5199-178	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/B.F./		Sherr and Webber, The ARF/p53 pathway.	
		Curr. Opin. Genet. Dev., 10:94-99, 2000	
		Shieh et al., DNA damage-induced phosphorylation of p53 alleviates inhibition MDM2.	
		Cell, 91:325-34, 1997	
		Slingerland and Pagano, Regulation of the cdk inhibitor p27 and its deregulation in cancer.	
		J. Cell Physi., 183:10-17, 2000	
		Stad et al., Mdmx stabilizes p53 and Mdm2 via two distinct mechanisms.	
		EMBO Rep., 2:1029-34, 2001	
		Stott et al., The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2.	
/B.F./		EMBO J., 17:5001-14, 1998	

Examiner Signature	/Brandon Fetterolf/	Date Considered	10/12/2007
--------------------	---------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known	
		Application Number	10/813,177
		Filing Date	03/29/04
		First Named Inventor	Wei Gu
		Art Unit	1646
		Examiner Name	to be assigned
Sheet 15 of 16	Attorney Docket Number	5199-178	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/B.F./		Tolbert et al., p19ARF is dispensable for oncogenic stress-induced p53-mediated apoptosis and tumor suppression in vivo.	
		Mol. Cell Biol., 22:370-77, 2002	
		Tyner et al., p53 mutant mice that display early ageing-associated phenotypes.	
		Nature, 415:45-53, 2002 (N/A)	
		Vogelstein et al., Surfing the p53 network.	
		Nature, 408:307-10, 2000	
		Wilkinson, K.D., Signal transduction: aspirin, ubiquitin and cancer.	
		Nature, 424:738-39, 2003	
		Wilkinson, K.D., Ubiquitination and deubiquitination: targeting of proteins for degradation by the proteasome.	
/B.F./		Semin. Cell Dev. Biol., 11:141-48, 2000	

Examiner Signature	/Brandon Fetterolf/	Date Considered	10/12/2007
--------------------	---------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known	
		Application Number	10/813,177
		Filing Date	03/29/04
		First Named Inventor	Wei Gu
		Art Unit	1646
		Examiner Name	to be assigned
Sheet 16	of 16	Attorney Docket Number	5199-178

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/B.F./		Wu et al., The p53-mdm-2 autoregulatory feedback loop.	
↓		Genes Dev., 7:1126-32, 1993	
↓		Yu et al., PUMA induces the rapid apoptosis of colorectal cancer cells.	
/B.F./		Molecular Cell, 7:673-82, 2001	

Examiner Signature	/Brandon Fetterolf/	Date Considered	10/12/2007
--------------------	---------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.